Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN17372 and Linvoseltamab in Relapsed/Refractory Multiple Myeloma
NCT07455851Phase 2Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2026
- Primary completion
- Sep 2033
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of REGN17372 in multiple myeloma (MM) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Dose Limiting Toxicities at 35 days, Treatment Emergent Adverse Events at 5 years and 2 more. Started Mar 2026; status: recruiting.
02
Drugs
REGN17372
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07455851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07455851.